Baudax Bio, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated and Combined Statements of Shareholders' Equity

Consolidated and Combined Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Separation	Public Offerings	Registered Direct Offerings	Equity Facility	Recro	Parent Company Net Investment	Parent Company Net Investment Recro	Common Stock	Common Stock Separation	Common Stock Public Offerings	Common Stock Registered Direct Offerings	Common Stock Equity Facility	Additional Paid in Capital	Additional Paid in Capital Separation	Additional Paid in Capital Public Offerings	Additional Paid in Capital Registered Direct Offerings	Additional Paid in Capital Equity Facility	Additional Paid in Capital Recro	Accumulated Deficit
Balance at Dec. 31, 2018	$ (68,347)						$ (68,347)
Stock-based compensation expense	499					$ 4,964		$ 4,964						$ 499
Issuance of common stock										$ 94					$ (94)
Issuance of common stock, Shares										9,350,709
Reclassification of parent company net investment							33,480													$ (33,480)
Net transfer from parent company	60,268						60,268
Contribution of cash by Recro Pharma, Inc. upon separation	19,000													19,000
Separation related adjustments	(548)																			(548)
Net loss	(32,557)						$ (30,365)													(2,192)
Balance at Dec. 31, 2019	(16,721)								$ 94					19,405						(36,220)
Balance, Shares at Dec. 31, 2019									9,350,709
Stock-based compensation expense	7,568					$ 1,773								7,568					$ 1,773
Issuance of common stock		$ 1	$ 14,973	$ 21,696	$ 3,612					$ 1	$ 77	$ 71	$ 4			$ 14,896	$ 21,625	$ 3,608
Issuance of common stock, Shares										45,874	7,692,308	7,100,000	441,967
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes	(475)								$ 7					(482)
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes, Shares									707,172
Warrants issued in connection with financing facility	1,423													1,423
Exercise of warrants value	5,593								$ 221					5,372
Exercise of warrants, Shares									22,163,676
Warrant exchange value	21,858								$ 12					21,846
Warrant exchange Shares									1,186,774
Net loss	(76,100)																			(76,100)
Balance at Dec. 31, 2020	$ (14,799)								$ 487					$ 97,034						$ (112,320)
Balance, Shares at Dec. 31, 2020									48,688,480